This 1-hour session will include 4 topic modules focused on the current management of biologically defined subsets of gastrointestinal cancer and emerging research information on novel agents and strategies under active investigation. Each module will employ an identical format and include:

• Audience Polling Using Keypad Devices
• Display of Steering Committee Responses to Related Clinical Questions
• Faculty Review of Select Data Sets

Each session will conclude with a 10-minute Q&A segment

STEERING COMMITTEE MEMBERS AND PARTICIPATING FACULTY

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancer.

Learning Objectives:

• Appreciate the recent FDA approval of TAS-102, and develop an evidence-based approach to integrate this agent into the management of metastatic colorectal cancer.
• Recognize the unique mechanism of action of, available clinical trial data with and clinical indications for the use of MM-398 for patients with treatment-refractory metastatic pancreatic cancer, and use this information to guide nonresearch treatment planning.
• Consider available clinical research data documenting the efficacy of ramucirumab in metastatic colorectal and gastric or gastroesophageal junction cancers, and discern how this agent can be optimally integrated into clinical practice for patients with these diseases.
• Educate patients with select gastrointestinal (GI) cancers regarding the potential side effects of recently approved agents, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.
• Develop an understanding of emerging Phase III efficacy data with and the potential clinical role of regorafenib in preparation for its potential introduction into the practical management of relapsed/refractory hepatocellular carcinoma.
• Appraise the biologic rationale for and available clinical data with investigational anti-PD-1 and/or anti-PD-L1 antibodies in the treatment of select GI cancers.
• Recall available and emerging data with other investigational agents currently in Phase III testing for various GI cancers, and, where applicable, refer eligible patients for trial participation or other expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statements:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
These activities are supported by educational grants from Boston Biomedical Pharma Inc, Exelixis Inc, Lilly, Merck and Merrimack Pharmaceuticals Inc.